> Markdown version of https://haygoodhealth.com/c/monoclonal-antibodies for AI agents. You are welcome here, and welcome back anytime. What an agent can do: https://haygoodhealth.com/agents .

# Monoclonal antibodies, given early - Haygood Health

A knowledge clinic for families

[Haygood Health](/)

[← Haygood Health](/)

### [Monoclonal antibodies, given early](/c/monoclonal-antibodies)

MechanismESTABLISHEDOutcomeB

Claimed

Monoclonal antibodies given early to high-risk outpatients reduce hospitalization and death.

What holds up

Neutralizing antibodies binding the spike receptor-binding domain to block ACE2-mediated cell entry is textbook virology, reproduced across labs and across multiple antibody products. In BLAZE-1 phase 3 (1,035 high-risk outpatients), bamlanivimab plus etesevimab cut COVID-related hospitalization or death by day 29 from 7.0% to 2.1% (70% relative reduction), with no deaths in the treatment arm versus ten in placebo. In the REGEN-COV phase 3 outpatient trial, hospitalization or death fell from 4.6% to 1.3% (71.3% relative reduction), with faster symptom resolution and viral-load decline. In RECOVERY's 9,785 inpatients, seronegative patients died at 24% vs 30% (rate ratio 0.79), a genuine mortality signal in patients lacking their own antibody response.

What it does not show

Two randomized trials in high-risk outpatients showed a real ~70% relative reduction in the hospitalization-or-death composite, and the large RECOVERY inpatient trial showed a 28-day mortality reduction confined to seronegative patients; but the composites were hospitalization-driven with few deaths and the inpatient benefit did not extend to unselected patients. There was no mortality benefit in unselected inpatients (overall rate ratio 0.94, not significant) and none in seropositive patients, and the ACTIV-3/TICO bamlanivimab inpatient arm was negative. Most importantly, the evidence is time-bound: spike mutations in Omicron and later variants escaped these antibodies' neutralization, ending their clinical utility, so the grade describes the 2020-2021 variant era and does not transfer to later variants.

Evidence for

Dougan M et al. (BLAZE-1 Investigators), N Engl J Med 2021;385(15):1382-1392, PMID 34260849, Weinreich DM et al. (Trial Investigators), N Engl J Med 2021;385(23):e81, PMID 34587383, RECOVERY Collaborative Group, Lancet 2022;399(10325):665-676, PMID 35151397, ACTIV-3/TICO LY-CoV555 Study Group, N Engl J Med 2021;384:905-914

Sources

VERIFIED Dougan M et al. (BLAZE-1 Investigators), N Engl J Med 2021;385(15):1382-1392, PMID 34260849. VERIFIED Weinreich DM et al. (Trial Investigators), N Engl J Med 2021;385(23):e81, PMID 34587383. VERIFIED RECOVERY Collaborative Group, Lancet 2022;399(10325):665-676, PMID 35151397. PENDING ACTIV-3/TICO LY-CoV555 Study Group, N Engl J Med 2021;384:905-914.

## Grade history (append-only)

Every grade change is kept, never overwritten, so the current grade and every prior one stay visible.

Mechanism gradeJustificationGraded byStateGraded at

ESTABLISHEDNeutralizing antibodies binding the spike receptor-binding domain to block ACE2-mediated cell entry is textbook virology, reproduced across labs and across multiple antibody products. In BLAZE-1 phase 3 (1,035 high-risk outpatients), bamlanivimab plus etesevimab cut COVID-related hospitalization or death by day 29 from 7.0% to 2.1% (70% relative reduction), with no deaths in the treatment arm versus ten in placebo. In the REGEN-COV phase 3 outpatient trial, hospitalization or death fell from 4.6% to 1.3% (71.3% relative reduction), with faster symptom resolution and viral-load decline. In RECOVERY's 9,785 inpatients, seronegative patients died at 24% vs 30% (rate ratio 0.79), a genuine mortality signal in patients lacking their own antibody response.admindisplayed2026-10-08T23:52:30.433Z

Outcome gradeJustificationGraded byStateGraded at

BTwo randomized trials in high-risk outpatients showed a real ~70% relative reduction in the hospitalization-or-death composite, and the large RECOVERY inpatient trial showed a 28-day mortality reduction confined to seronegative patients; but the composites were hospitalization-driven with few deaths and the inpatient benefit did not extend to unselected patients. There was no mortality benefit in unselected inpatients (overall rate ratio 0.94, not significant) and none in seropositive patients, and the ACTIV-3/TICO bamlanivimab inpatient arm was negative. Most importantly, the evidence is time-bound: spike mutations in Omicron and later variants escaped these antibodies' neutralization, ending their clinical utility, so the grade describes the 2020-2021 variant era and does not transfer to later variants.admindisplayed2026-10-08T23:52:30.434Z

[Submit evidence for or against this claim](/submit?claim=monoclonal-antibodies)

Want to hear what's next for Haygood Health?

Email me about it

Add my name and number (optional)

No spam. One email when there is something to show, and you can reply to a real person.